enGene Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $110.18M
- P/E (TTM)
- 0.7
- Dividend yield
- 0.00%
About enGene Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
enGene Holdings Inc. is a clinical-stage biotechnology company developing targeted genetic medicines delivered to mucosal tissues. Utilizing its proprietary DDX non-viral gene delivery platform, the company focuses on creating therapies for localized, high-unmet-need diseases. Its primary product candidate is detalimogene voraplasmid, an investigational treatment being evaluated in clinical trials for non-muscle invasive bladder cancer, specifically targeting patients with Bacillus Calmette-Guérin-unresponsive disease. The organization manages its research and development operations as a single business segment directed at treating bladder cancer patients.
The company conducts its operations across Canada and the United States, utilizing corporate and laboratory facilities to advance its clinical pipeline. enGene maintains its principal executive offices in Saint-Laurent, Quebec, Canada.
Summary of the business section of enGene Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- enGene Therapeutics Inc.
- Headquarters
- Saint-Laurent, Quebec, Canada
- Address
- 4868 Rue Levy, Suite 220
- Phone
- (514) 332-4888
- Website
- engene.com
- Employees
- 82, Oct 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Z4
- Fiscal year ends
- October 31
- Auditor
- KPMG LLP, Montreal, Canada
Stock & identifiers
- Ticker
- ENGN
- Other tickers
- ENGNW
- Exchange
- Nasdaq
- IPO date
- Feb 1, 2022
- Shares outstanding
- 67M, Sep 2, 2026
- Public float
- $154.18M, Apr 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1980845
- CUSIP
- 29286X101
- ISIN
- US29286X1019
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| William Grossman | Interim Chief Medical Officer, Director | 5,102 |
| Ronald Harold Wilfred Cooper | CEO & President, Director | 10,000 |
| Constantine Chinoporos | Interim Chief Business Officer | – |
| Kathleen P. Richton | SVP, Finance and Treasurer | 6,900 |
| Alexander Julian Nichols | Chief Strategy & Ops. Ofc | – |
| Jill Buck | Chief Development Officer | – |
| Anthony Tzeyew Cheung | Chief Scientific Officer | 102,873 |
| D. Ryan Daws | Chief Financial Officer | – |
| Lee Giguere | Chief Legal Ofc. and Corp Secy | – |
| Joan Connolly | Chief Technology Officer | – |
| Matthew Ross Boyd | Chief Regulatory Officer | 7,500 |
| Hussein Sweiti | Chief Medical Officer | – |
| Amy Pott | Chief Global Comm. Ofc. | – |
| Raj Som Pruthi | Chief Medical Officer | – |
| Philip Astley-Sparke | Director | 20,000 |
| Michael Thomas Heffernan | Director | – |
| Richard M. Glickman | Director | 24,675 |
| Lota S. Zoth | Director | – |
| Wouter Joustra | Director | – |
| Gerald A. Brunk | Director | 238,851 |
| Paul J. Hastings | Director | – |
| Jasper Bos | Director | – |
Employees
Headcount reported in annual reports
“As of October 31, 2025, we had 82 employees, including 81 full-time employees, 51 of whom were primarily engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 9, 2026 | Name change | Name changed from enGene Holdings Inc. to enGene Therapeutics Inc. |
| Oct 31, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 31, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 9, 2023 | Merger | Registration of securities for a merger or exchange offer (S-4) |